ARCHIVES

Ethicists dispute von Eschenbach’s claim that his NCI-FDA conflicts are managed. NCI-FDA chief appears to cite Klausner-era “in-box rule.”

This article is from The Cancer Letter archive.

Vol. 31 No. 46 | December 16, 2005

Download PDF Visit The Full Archive

Related Articles

FDA Guidance for Public Comment at Advisory Committee Meetings

December 10, 2010

Abstracts Of Papers Presented By Breast Cancer Task Force

September 17, 1976

NCAB Asks NCI To Delay Proposed change In Breast Cancer Screening Guidelines

November 26, 1993

Panel Unenthused About New Toxicity Testing Program

December 15, 1978

“Clinical research of all kinds in the IRP lacks a rigorous, centralized process for peer review.”

July 21, 1995

Mammography’s Best Role Is Screening, Kopans Assert

March 18, 1994